REDWOOD CITY, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a preclinical-stage biopharmaceutical company focused on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers, announced the appointment of Franco Valle as Chief Financial Officer. Mr. Valle is an accomplished financial expert who brings extensive experiences to Biomea, in particular with building the necessary infrastructure to support clinical and operational growth within biotech companies. Mr. Valle will also assume the role of Principal Financial Officer and Principal Accounting Officer upon joining. Recently, Mr. Valle se

–Completed acquisition of Eidos Therapeutics, allowing BridgeBio to deploy its full clinical and commercial infrastructure to develop and plan for potential global commercialization upon regulatory approval of Eidos’ product candidate, acoramidis, a potential best-in-class therapy for patients with amyloidosis cardiomyopathy (ATTR-CM) –New Drug Application (NDA) for infigratinib for the treatment of cholangiocarcinoma accepted by the U.S. Food and Drug Administration (FDA) under Priority Review designation and Real-Time Oncology Review (RTOR) pilot program, designed to expedite the delivery of safe and effective cancer treatments to patients –Initiated two new clinical trials since las

PALO ALTO, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) today announced that it has completed its acquisition of all of the outstanding shares of Eidos Therapeutics, Inc. (“Eidos”) (formerly Nasdaq: EIDX) common stock that BridgeBio did not already own. The transaction was overwhelmingly approved by BridgeBio and Eidos stockholders.  The merger reunites the teams at BridgeBio and Eidos and allows BridgeBio to deploy its full clinical and commercial infrastructure to support the development and global commercialization plans underway for Eidos’ acoramidis, a potential best-in-class therapy for patients with transthyretin (TTR) amyloidosis

PALO ALTO, Calif. and SAN FRANCISCO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) today announced that the stockholders of each of BridgeBio and Eidos voted to approve all proposals related to BridgeBio’s acquisition of all of the outstanding shares of Eidos common stock that BridgeBio does not already own. The merger is expected to close on or about January 26, 2021, subject to the satisfaction or waiver of other conditions to closing. At a special meeting of Eidos stockholders held virtually today, Eidos stockholders approved the adoption of the previously disclosed merger agreement with B

PALO ALTO, Calif. and SAN FRANCISCO, Jan. 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) announced today that the acquisition of shares of common stock of Eidos not held by BridgeBio or its subsidiaries, on the terms and subject to the conditions of their previously announced merger agreement, is expected to close on or about January 26, 2021. The closing of the transaction is subject to the receipt of approvals from BridgeBio and Eidos stockholders at special meetings of each company’s stockholders, both of which are scheduled for January 19, 2021, and the satisfaction or waiver of other conditions to

PALO ALTO, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced that leading proxy advisory firm Institutional Shareholder Services (“ISS”) recommends that BridgeBio stockholders and Eidos Therapeutics, Inc. (Nasdaq: EIDX) stockholders vote “FOR” BridgeBio’s proposed merger with Eidos and each of the other proposals to be considered at both companies’ virtual special meetings to be held on January 19, 2021.  Under the proposed merger agreement, BridgeBio has agreed to acquire all of the outstanding common stock of Eidos it does not already own, representing approximately 36.3% of Eidos’ outstanding shares. Eidos stockholders will have the right t

15-12B - Eidos Therapeutics, Inc. (0001731831) (Filer)

EFFECT - Eidos Therapeutics, Inc. (0001731831) (Filer)

POS AM - Eidos Therapeutics, Inc. (0001731831) (Filer)

S-8 POS - Eidos Therapeutics, Inc. (0001731831) (Filer)

S-8 POS - Eidos Therapeutics, Inc. (0001731831) (Filer)

S-8 POS - Eidos Therapeutics, Inc. (0001731831) (Filer)

25-NSE - Eidos Therapeutics, Inc. (0001731831) (Subject)

8-K - Eidos Therapeutics, Inc. (0001731831) (Filer)

8-K - Eidos Therapeutics, Inc. (0001731831) (Filer)

4 - Eidos Therapeutics, Inc. (0001731831) (Issuer)